Browsing by Author "Ergene U."
Now showing 1 - 9 of 9
Results Per Page
Sort Options
Item Factors influencing emergency department arrival time and in-hospital management of patients with acute myocardial infarction(2006) Ayrik C.; Ergene U.; Kinay O.; Nazli C.; Unal B.; Ergene O.Reperfusion of the infarct-related artery in the very first hour ("golden hour") of acute myocardial infarction (AMI) significantly reduces mortality rates. Several factors may delay the initiation of reperfusion therapy (ie, thrombolytic therapy or primary percutaneous transluminal coronary angioplasty [PCTA]), most of which are related to patients. A total of 520 patients with suspected AMI were evaluated in the emergency department of Dokuz Eylül University Hospital between March 1996 and October 1999. After inclusion criteria were applied, the study consisted of 178 patients with a history of AMI. Analyzed data that affected patients' arrival to the hospital were obtained from responses to a questionnaire. The Statistical Package for the Social Sciences (SPSS; SPSS Inc., Chicago, III), version 11.0, was used for all statistical analyses. The mean "symptom onset-hospital arrival time" was 188±325 min for the entire study group. The median delay was 110 min (∼2 h). Only 39 (22%) patients arrived to the hospital within the first hour. The mean time needed for late responders (n=109, 74%) (hospital arrival later than 1 h after symptom onset) to arrive was 245±363 min. According to the results of this study, many patients with AMI who may be eligible for reperfusion therapy miss the "golden hour" because of late hospital arrival. Some groups of patients (ie, elderly, women, those with diabetes) were especially late in arriving. To reduce such delays, training programs may be advised to focus on these groups of patients. Arrival times to the hospital during AMI can be greatly improved by efficient public education programs targeted to these groups. ©2006 Health Communications Inc.Item Aplastic anemia, mucormycosis and aspergillosis in infectious mononucleosis: Success is possible(2007) Ergene U.; Ozbalci D.; Baykal B.; Metin Ciris I.; Yariktas M.Infectious mononucleosis (IM) is a rare cause of aplastic anemia in adults. We report of a patient in whom aplastic anemia, mucormycosis and aspergillosis complicated during the course of IM and successfully treated with liposomal amphotericin B. According to our searches in literature, we could not find a similar patient complicated and successfully treated like ours. © 2007 Elsevier Ltd. All rights reserved.Item Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT)(2007) Ergene U.; Çaǧirgan S.; Pehlivan M.; Yilmaz M.; Tombuloǧlu M.Autologous peripheral blood stem cells transplantation (PBSCT) is a therapeutic option which can be used in various hematological neoplastic disorders; and it can prolong disease free survival and total survival and at times it may be curative. In this study, we investigated variables influencing PBSCT in 91 patients who had undergone PBSCT between 1998 and 2002 in our center, retrospectively. PBSC collection was performed after mobilization with G-CSF or chemotherapy plus growth factor. Only high dose chemotherapy was used for conditioning regimes. The median number of CD34+ was 11.5 × 106/kg. Posttransplant neutrophil engraftment (>500/μL) was requiring a median of 10 days, it was 13 days for platelet engraftment (>20,000/μL). For neutrophil and platelet engraftment, we investigated; sex, age, diagnosis and CD34+ cells, the time interval between diagnosis and transplantation, number of apheresis, conditioning regime, growth factor initiation day as independent variables. In univariate analysis CD34+ cell number (>10 × 106/kg), time interval more than one year between diagnosis and transplantation and BEAM conditioning was found to be significant for neutrophil engraftment. But in multivariate analysis none of them was found to be significant. For platelet engraftment in univariate analysis CD34+ cell number (>7 × 106/kg), primary diagnosis of multiple myeloma initiation day of growth factor (>2 day) was found to be significant. In multivariate analyses only CD34+ cell count was found to be significant (p = 0.005). In conclusion, as in previous studies we found that the only predictor of engraftment kinetics was CD34+ cell count. © 2006.Item A patient with both hairy cell leukemia and subacute thyroiditis(2007) Ergene U.; Ozbalci D.; Akin H.Background: Hairy cell leukemia (HCL) presents with pancytopenia, splenomegaly, and monocyte-like hairy cells with eccentric nucleus in blood smear and bone marrow. Cladribine, pentostatin and interferon alpha are used for therapy. Fever is usually associated with infections of bacterial or viral origin. High mortality and morbidity are associated with bacterial infections in those who are untreated. Case Report: We report a 38 years old male HCL patient representing with fever and pain on the neck. The diagnosis of febrile neutropenia and subacute thyroiditis were made. For the therapy of subacute thyroiditis, paracetamol and propranolol were given. The patient had refused to take chemotherapy, so, when the thyroid function test reached the normal ranges, splenectomy was performed with the support of erythrocytes and platelet aphaeresis. At the follow up, the patient was in good state of health. Conclusions: Subacute thyroiditis should be kept in mind especially in HCL representing with fever and pain over the thyroid. According to our search on medical database, this is the first reported case of HCL with subacute thyroiditis in literature.Item Brucellosis: A rare cause of febrile neutropenia in acute myeloblastic leukemia(2011) Ozbalci D.; Ergene U.; Cetin C.B.Brucellosis is a zoonotic disease and endemically seen in the Middle East, Eastern Europe and continental America. Febrile neutropenia related to Brucellosis has been reported only in a few cases. Brucella was cultured from the bone morrow of a 42-year-old woman who was admitted to hospital with symptoms of fever and fatigue and later diagnosed as acute myeloblastic leukemia (AML). The patient was treated for both AML and Brucellosis without any problems and discharged from the hospital after scheduling her follow-up visits. Brucellosis might be considered in the etiology of febrile neutropenia in endemic regions and must be treated effectively to prevent possible morbidity and mortality during or after chemotherapy. © 2010 Springer Science+Business Media, LLC.Item Use of cytarabine and idarubicin in a newly diagnosed AML patient with a severe wound(2011) Bozoglan H.; Ergene U.; Yoleri L.Acute myeloid leukemia (AML) is malignant tumor of haemopoietic precursor cells of non-lymphoid lineage. AML can atypically present with non-spesific cutaneous lesions or wounds. There are rare acute leukemia cases which present with genital ulcerations or pyoderma gangrenosum in the literature. The effect of acute leukemia on wound healing is not known, but it is thought that cytopenias and chemotherapy can impair wound healing in patients with leukemia. The effects of chemotherapeutic agents on wound healing are arguable. Here we present wound care strategies and simultaneously applied chemotherapy in an AML patient. © 2011 Elsevier Ltd.Item A chronic eosinophilic leukemia patient presenting with blurred vision; [Bulanik görmeyle başvuran kronik eozinofilik lösemi hastasi](2011) Özbalci D.; Ergene U.; Yazgan H.[No abstract available]Item H1N1 as a causative agent in febrile neutropenia of an acute myeloid leukaemia (AML) patient(2012) Ergene U.; Ozbalci D.; Tunger O.[No abstract available]Item Successful management of imatinib despite alopecia and nail necrosis(2013) Ergene U.; Ozbalci D.Imatinib mesylate selectively inhibits bcr/abl and other non-specific tyrosine kinases, such as c-kit and platelet derived growth factor (PDGF) receptor and successfully used to treat chronic myeloid leukaemia (CML). In most cases, the drug is well tolerated: however, side effects can be seen. Hair loss and paronychia inflammation were often reported with Imatinib, but total alopecia was rarely mentioned. We report a CML patient who was presented with alopecia and paronychia inflammation probably induced by imatinib therapy. We have successfully treated our patient by cessation and then re-applying therapy with lower doses after improvement of lesions and have not found a similar report in literature. © 2013 Elsevier Ltd.